The therapeutic response of these neoplasms to the administration of TRK inhibitors such as larotrectinib and entrectinib is surprisingly favorable, and may provide a promise to this cancer population with a personalized treatment of all neoplasms with NTRK gene fusions [14]. This evidence concerns the gene TPM3 and neoplasm.